ArticleJournal of gastrointestinal oncology2026
A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extrahepatic cholangiocarcinoma (ECC) is a highly aggressive malignancy. This study aimed to develop and validate a comprehensive prognostic nomogram incorporating treatment data to enable individualized risk stratification and refine patient selection for palliative interventions. Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) program (for the period from 2018 to 2022). There were 2,254 patients identified and randomly divided into model development (n=1,577) and validation (n=677) cohorts. Prognostic factors were selected through multivariate Cox regression using backward elimination based on the Akaike Information Criterion (AIC). A nomogram was developed to estimate 6-month, 1-year, and 3-year survival probabilities. Model performance was evaluated using the consistency index (C-index), calibration curves, and decision curve analysis (DCA). Finally, risk stratification cutoffs were determined to facilitate individualized prognostic assessment in palliative settings. Results: The final nomogram incorporated age, N stage, M stage, surgery, and chemotherapy status. The model demonstrated good discrimination, with C-indices of 0.770 [95% confidence interval (CI): 0.750-0.790] in the training cohort and 0.789 (95% CI: 0.768-0.802) in the validation cohort. Calibration curves indicated good agreement between predicted and observed probabilities. DCA revealed good net benefit across clinically relevant threshold probabilities. Risk stratification identified high-risk (<3 months, score ≥70), intermediate-risk (3-12 months, score 59-69), and low-risk (>1 year, score ≤58) groups, potentially guiding the selection between plastic and metal stents in palliative settings. Conclusions: This prognostic model provides accurate individualized survival prediction for ECC and facilitates objective risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.